CMS May Expand Opioid Abuse Measures To Other Classes In Part D, Insurers Told
This article was originally published in The Pink Sheet Daily
Executive Summary
At the AHIP Medicare conference, CMS official Andrea Bendewald presents preliminary data indicating the agency’s measures for preventing opioid abuse are having the desired effect. She also discusses formulary edits in the upcoming 2014 Part D plans aimed at curtailing overuse of opioids and other “high risk medications.”
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.